WOS
Permanent URI for this collectionhttps://hdl.handle.net/11443/932
Browse
2 results
Search Results
Item Increased Serum Nesfatin-1 Levels in Patients with Impaired Glucose Tolerance(GALENOS YAYINCILIK, 2017-01-01) Akin, Safak; Gulcelik, Nese Ersoz; Aksoy, Duygu Yazgan; Karakaya, Jale; Usman, AydanPurpose: Nesfatin-1 is a recently discovered energy-regulating peptide, widely expressed in both central and peripheral tissues. It is involved in various functions, such as the stimulation of hypothalamic-pituitary-adrenal axis and sympathetic nervous system, influencing visceral functions, water intake, and regulation of temperature and emotions. It exerts a direct glucose-dependent insulinotropic action on the beta cells of pancreatic islets. The current study evaluated nesfatin-1 levels and insulin response to glucose load in patients with impaired glucose tolerance (IGT) and in healthy subjects. Material and Method: Of those patients who underwent the oral glucose tolerance test (OGTT), 14 with IGT and 13 body mass index-(BMI) and age-matched healthy subjects as controls were included in the study. Blood samples were taken at 0, 60 and 120 min, and the glucose, insulin, and nesfatin-1 levels were measured. Results: The basal levels of glucose, insulin, and nesfatin-1 were significantly higher in the patients with IGT than in controls. Two-way repeated measures ANOVA revealed that change in time (CIT) for glucose and insulin during an OGTT was significant (p<0.001 and p<0.001, respectively). CIT for glucose and insulin was significantly different between the IGT patients and the controls (p<0.001 and p=0.003, respectively). CIT for nesfatin-1 was not significant (p=0.406) and did not differ significantly between the two groups (p=0.331). Discussion: The elevated levels of basal nesfatin-1 were observed in the patients with IGT. There was no change in the absolute nesfatin-1 levels in response to glucose load in either group. The increase in the levels of basal nesfatin-1 may reflect a compensatory mechanism to regulate the impaired glucose metabolism in the IGT patients, which is later underwhelmed with the onset of diabetes.Item Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma(TUBITAK SCIENTIFIC \& TECHNICAL RESEARCH COUNCIL TURKEY, 2017-01-01) Akin, Safak; Aksoy, Duygu Yazgan; Akin, Serkan; Kilic, Mehmet; Yetisir, Fahri; Bayraktar, MiyaseBackground/aim: The purpose of this study was to analyze the clinicopathological characteristics of patients with papillary thyroid carcinoma (PTC) and papillary thyroid microcarcinoma (PTMC) and predictive factors for central lymph node metastasis (CLNM). Materials and methods: Patients diagnosed as having PTC and PTMC were evaluated. Clinical and laboratory parameters were recorded. Results: The mean age at diagnosis was 47.3 +/- 11.9 years. Of all 223 patients, 91 (40.8\%) had lymph nodes removed, 29 of whom had lymph node metastasis and 24 of whom had only CLNM. Univariate analysis revealed that central lymph node metastasis was associated with male sex, presence of bilaterality, presence of extrathyroidal extension, and tumor size (P = 0.033, P = 0.027, P < 0.001, P < 0.001, respectively). However, multivariate logistic regression analysis showed that sex, age, tumor size, multifocality, bilaterality, extrathyroidal extension, clinical suspicion, and chronic lymphocytic thyroiditis were not significantly correlated with an increased risk for CLNM. Conclusion: Lymph node metastasis is known to be a significant predictor of locoregional recurrence in patients with PTC and PTMC. Further prospective studies are needed to identify the extent of surgery such as central lymph node dissection in patients with PTC or PTMC.